Reviewing depot injection efficacy in the treatment of schizophrenia
CPD Previous     Next

Reviewing depot injection efficacy in the treatment of schizophrenia

Adrian Jones Clinical academic lead, Betsi Cadwaladr University Health Board, Mold, North Wales
Martin Jones Associate professor, associate dean research and director, Department of Rural Health, University of South Australia, Whyalla, Australia

Schizophrenia is a severe and enduring mental health disorder. Treatment includes antipsychotic medication and psychological interventions. Medication can be administered as a depot injection; these treatments reduce the risk of relapse in some people with schizophrenia who have difficulties adhering to oral medication regimens. This article outlines the types of depot and medications that are available for the treatment of schizophrenia, and discusses the evidence base supporting their efficacy. The role of antipsychotic medication as part of a treatment plan should be reinforced by enabling patients to make an informed choice about which medication best supports their health and wellbeing.

Nursing Standard. 30, 33, 50-60. doi: 10.7748/ns.30.33.50.s45


Peer review

All articles are subject to external double-blind peer review and checked for plagiarism using automated software.

Received: 11 April 2015

Accepted: 14 January 2016

Want to read more?

Already subscribed? Log in


Unlock full access to RCNi Plus today

Save over 50% on your first 3 months

Your subscription package includes:
  • Unlimited online access to all 10 RCNi Journals and their archives
  • Customisable dashboard featuring 200+ topics
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests
RCN student member? Try Nursing Standard Student

Alternatively, you can purchase access to this article for the next seven days. Buy now